STAT+: A former AI regulator, now in industry, says biopharma is reading FDA’s guidance wrong

Tala Fakhouri, who previously worked at the FDA on AI policy, now at Parexel, criticizes the biopharma industry for misinterpreting the FDA's flexible guidance in conservative ways to avoid risk. The article highlights concerns about how industry implementation diverges from the FDA's intended approach.